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MaBACKGROUND Patients with protein-losing enteropathy (PLE) following the Fontan operation have a reported 50%
mortality at 5 years after diagnosis.
OBJECTIVES The aim of this study was to review outcomes in patients with PLE following the Fontan operation.
METHODS From 1992 to 2010, 42 patients (55% male) with PLE following the Fontan operation were identiﬁed from
clinical databases at the Mayo Clinic. Data were collected retrospectively.
RESULTS Mean age at PLE diagnosis was 18.9  11.0 years. Initial Fontan operation was performed at 10.1  10.8 years
of age. Mean time from Fontan operation to PLE diagnosis was 8.4  14.2 years. Survival was 88% at 5 years. Decreased
survival was seen in patients with high Fontan pressure (mean >15 mm Hg; p ¼ 0.04), decreased ventricular function
(ejection fraction <55%; p ¼ 0.03), and New York Heart Association functional class >2 at diagnosis (p ¼ 0.04). Patients
who died had higher pulmonary vascular resistance (3.8 1.6 Wood units [WU] vs. 2.1  1.1 WU; p ¼ 0.017), lower cardiac
index (1.6  0.4 l/min/m2 vs. 2.7  0.7 l/min/m2; p < 0.0001), and lower mixed venous saturation (53% vs. 66%; p ¼
0.01), compared with survivors. Factors were assessed at the time of PLE diagnosis. Treatments used more frequently in
survivors with PLE included spironolactone (21 [68%]), octreotide (7 [21%]), sildenaﬁl (6 [19%]), fenestration creation
(15 [48%]), and relief of Fontan obstruction (7 [23%]).
CONCLUSIONS PLE remains difﬁcult to treat; however, in the current era, survival has improved with advances in
treatment. Further study is needed to better understand the mechanism of disease and ideal treatment strategy.
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ABB R E V I A T I O N S
AND ACRONYMS
EF = ejection fraction
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55for patients with PLE following the Fontan opera-
tion (7).
The purpose of this study was to determine the
survival of patients with PLE following the Fontan
operation in the current era. We sought to identify
factors associated with patient mortality and to re-
view treatment strategies used in survivors.
METHODS
Patients with PLE following the Fontan operation
who were seen at the Mayo Clinic between 1992 and
2010 were identiﬁed from clinical databases. Of the
42 patients identiﬁed, 25 (60%) had their original
Fontan operation performed at the Mayo Clinic,
whereas 17 (40%) had their original Fontan operation
performed elsewhere. Data were collected by retro-
spective chart review. Surgical details, treatment
course, and response to treatment as assessed by
laboratory assessment and clinical improvement
were recorded. Echocardiograms and cardiac cathe-
terization data were reviewed for the presence
of valvular regurgitation, ventricular function (esti-
mated ejection fraction [EF]), cardiac output,
pulmonary vascular resistance, and intracardiac
pressures, including ventricular end-diastolic pres-
sure. Cardiac catheterization data were obtained
within 2 years following diagnosis in most patients.
For 5 patients, data were obtained from catheteriza-
tions 3 to 5 years following diagnosis. Fontan pres-
sures were measured in the Fontan pathway. In cases
of Fontan obstruction, pressures following relief of
obstruction were recorded. Serum albumin levels,
total protein levels, and fecal alpha 1 antitrypsin
clearance at diagnosis were recorded. Survival was
ascertained through medical record review and
conﬁrmed through Accurint (LexisNexis, New York,
New York). The protocol was approved by the Mayo
Clinic Foundation’s institutional review board (Pro-
tocol 10-004994).
Patients in this cohort presented with clinical
symptoms or decreased serum albumin levels. The
diagnosis of PLE was made through a combination
of clinical symptoms (peripheral edema, diarrhea,
abdominal pain, or effusions within the pericardial
or pleural space), elevated fecal alpha-1 antitrypsin
clearance (>50 ml/24 h or elevated spot fecal alpha
1 antitrypsin concentration [>100 mg/ml]), and
serum albumin <3.0 g/dl. The presence of 1 clinical
feature with both laboratory abnormalities was
needed for diagnosis. Patients with other primary
causes of hypoproteinemia, such as nephrotic syn-
drome or intestinal lymphangiectasia (n ¼ 1), were
excluded as were patients with known inﬂammatorybowel disease, such as Crohn’s disease or ul-
cerative colitis.
STATISTICAL ANALYSIS. Continuous vari-
ables are expressed as mean  SD or median
(interquartile range) when appropriate. Dif-
ferences in median age and time intervals
from surgery were examined using the Wil-
coxon rank-sum test. Frequencies with proportions
were determined for categorical variables. Survival
curves were generated through Kaplan-Meier analysis
and compared using log-rank tests. Laboratory and
hemodynamic variables were further analyzed
through the chi-square test. The Fisher exact test was
used when appropriate to account for small sample
size distribution. Due to the small sample size, vari-
ables were examined through a univariate analysis
only. All statistical analyses were conducted using
SAS version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
PATIENT DEMOGRAPHICS. Forty-two patients with
PLE following a Fontan operation were identiﬁed.
Patient demographics are summarized in Table 1. The
mean time from diagnosis to last follow-up was
8.4  6 years (range 1 to 22 years). Mean age at
follow-up was 26.5  11.6 years (range 5 to 58 years).
Underlying cardiac anatomy was tricuspid atresia
in 12 patients (29%), double inlet left ventricle in 11
patients (26%), unbalanced atrioventricular septal
defect in 7 patients (17%), pulmonary atresia with
intact ventricular septum in 4 patients (10%), mitral
atresia with double outlet right ventricle in 3 pa-
tients (7%), mitral atresia in 2 patients (5%), hypo-
plastic left heart syndrome in 1 patient (2%), Shone
syndrome in 1 patient (2%), and L-transposition of
the great arteries with straddling left atrioventricular
valve in 1 patient (2%). The predominant mor-
phology was left ventricular in 27 patients (64%).
SURGICAL HISTORY. All patients had surgical pro-
cedures before the Fontan operation. There was no
association between the number or type of prior
surgical procedures and decreased survival in pa-
tients diagnosed with PLE after the Fontan operation.
Initial Fontan operations were performed between
1974 and 2005; one-half of this cohort underwent
surgery after 1990. Nine patients had surgery before
1985. Six of the 11 patients who died had their initial
Fontan operation before 1985. Two patients had
atrioventricular valve replacements before PLE diag-
nosis, due to severe valve regurgitation. Six patients
had fenestrations placed at the initial Fontan opera-
tion. One patient had a Fontan fenestration created in






(n ¼ 11) p Value
Total Cohort
(N ¼ 42)
Median age at PLE diagnosis, yrs 14 (4.7–57) 22 (12–39) 0.01 17 (4.7–57)
Median age at Fontan operation, yrs 8 (2–38) 11.9 (2–37) NS 8.3 (2–38)
Median time: Fontan operation
to PLE, yrs
6.5 (1–27) 10.4 (1–20) NS 7.8 (1–27)
Male 16 (52) 7 (64) NS 23 (55)
Type of initial Fontan operation NS
Atriopulmonary connections 19 (61) 9 (81) 28 (67)
Lateral tunnel or intra-atrial conduit 4 (13) 2 (19) 6 (14)
Extracardiac conduit 8 (26) 0 8 (19)
Predominant ventricular morphology NS
Left 19 (61) 8 (73) 27 (64)
Right 12 (39) 3 (27) 15 (36)
Values are mean (range) or n (%).
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56the Fontan operation, due to recurrent pleural effu-
sions. Two patients had patent fenestrations at the
time of PLE diagnosis.
PATIENT SURVIVAL. Survival was 88% at 5 years af-
ter diagnosis of PLE (Fig. 1). There were 11 deaths.
Mean age at death was 32  7.7 years of age (range 22
to 47 years). Mean time interval from diagnosis to
death was 7.5  5.4 years (range 1 to 18 years). Causes
of death included sepsis (n ¼ 7), complications after
Fontan conversion (n ¼ 1), and unknown (n ¼ 3).0 2 4 6 8 10
95% CI
Time Since Diagnosis (Years)
35 30 22 18 14
s 3 2 1 4
1 Survival Curve for Patients With PLE After
tan Operation
in this patient cohort was 88% at 5 years after protein-losing
athy PLE diagnosis.Factors associated with decreased survival in-
cluded high Fontan pressure (mean >15 mm Hg;
p ¼ 0.04), decreased ventricular function (estimated
EF <55%; p ¼ 0.01), and New York Heart Association
(NYHA) functional class >II (p ¼ 0.03) at diagnosis
(Fig. 2). Patients with Fontan pressures >15 mm Hg at
the time of diagnosis of PLE had 5- and 10-year sur-
vival rates of 83% and 63%, respectively. In contrast,
patients with Fontan pressures <15 mm Hg had 5- and
10-year survival rates of 95% and 86%, respectively.
Similarly, patients with estimated EF of <55% had
5- and 10-year survival rates of 87% and 62%,
compared with 91% and 85% in patients with EF
>55%. NYHA functional class III or IV at time of
diagnosis was associated with decreased 5- and
10-year survival, with rates of 83% and 45% versus
95% at both 5 and 10 years in patients with NYHA
functional class I or II.
Patients who died had higher pulmonary vascular
resistance (3.8  1.6 Wood units [WU] vs. 2.1  1.1 WU;
p ¼ 0.017), lower cardiac index (1.6  0.4 l/min/m2 vs.
2.7  0.7 l/min/m2; p < 0.0001), and lower mixed
venous oxygen saturation (53% vs. 66%; p ¼ 0.01),
compared with survivors (Table 2). Laboratory as-
sessment revealed that serum creatinine levels were
signiﬁcantly higher in patients who died compared
with those in survivors (1.34  0.40 mg/dl vs. 0.84 
0.33 mg/dl; p ¼ 0.03). Ventricular end-diastolic
pressure, serum hemoglobin levels, serum albumin
levels, and fecal alpha 1 antitrypsin levels were not
signiﬁcantly different in survivors versus non-
survivors (Table 2).
Atrial tachyarrhythmias were present in 28 patients
(67%). Patients with atrial arrhythmias had decreased
survival at both 5 and 10 years, although the differ-
ences were not statistically signiﬁcant (p ¼ 0.07)
(Fig. 2D). Therapies to control arrhythmias included
radiofrequency ablation in 23 patients, antiarrhythmic
medications in 28 patients, pacemaker therapy in
17 patients, and Fontan conversion in 9 patients.
MEDICAL AND SURGICAL THERAPY. Medical therapy
only (n ¼ 15) resulted in symptomatic improve-
ment in 7 patients (47%), no improvement in 5 (33%),
and death in 3 (20%). Medical plus surgical/interven-
tional procedures (n ¼ 27) resulted in symptomatic
improvement in 10 patients (37%), no improvement in
9 (33%), and death in 8 (30%). Types of therapies used
are described in Table 3. Medical therapies used more
frequently in survivors versus nonsurvivors included
spironolactone, octreotide, and sildenaﬁl. Surgical
therapies used more frequently in survivors included
fenestration placement and relief of obstruction
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NYHA Class Atrial Arrhythmias
No arrhythmia
+ arrhythmia
Class 1 or 2
Class 3 or 4
#pts followed
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FIGURE 2 Factors Affecting Survival in Patients With PLE After the Fontan Operation
Fontan pressure <15 mm Hg (A), ventricular function >55% (B), and New York Heart Association (NYHA) functional class III or IV (C) at time of
diagnosis were associated with decreased survival. The presence of atrial arrhythmias (D) was also associated with decreased survival, although
this association was not statistically signiﬁcant. EF ¼ ejection fraction; other abbreviation as in Figure 1.
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57In addition to the medical therapies described,
intravenous immunoglobulin therapy was used in
3 patients and inﬂiximab was used in 1 patient.TABLE 2 Laboratory and Hemodynamic Assessments at




(n ¼ 11) p Value
PVR, WU 2.1  1.1 3.6  1.6 0.017
Cardiac index, l/min/m2 2.7  0.7 1.6  0.4 0.02
Mixed venous saturation, % 66.0  8.1 53.0  7.8 0.01
Creatinine, mg/dl 0.84  0.33 1.34  0.4 0.03
Albumin, mg/dl 2.5  0.6 2.4  0.6 NS
Stool alpha 1 antitrypsin, mg/dl 321  179 371  138 NS
Hemoglobin, mg/dl 14.0  3.3 13.0  1.8 NS
Ventricular end-diastolic pressure,
mm Hg
11  3 10  2 NS
Values are mean  SD.
PVR ¼ pulmonary vascular resistance; WU ¼ Wood units; other abbreviations as
in Table 1.Intravenous diuretic agents with or without albumin
therapy were used in 37 patients (90%), primarily
during symptomatic periods. Mean albumin level at
time of follow-up was 3.3  0.96 mg/dl. Additional
surgical therapies included Fontan takedown in 2
patients; 1 had symptomatic relief, whereas the other
remained with PLE-related symptoms. One patient
had additional coiling of venovenous collateral.
Cardiac valve repair, closure, or replacement was
used in 4 patients who had severe valve regurgita-
tion. Cardiac transplantation was performed in
1 patient at the time of this review, and it resulted in
resolution of PLE.
DISCUSSION
PLE after the Fontan operation remains a difﬁcult
complication to treat. Historically, survival following
diagnosis has been dismal, with mortality rates of
50% at 5 years after diagnosis (1,2). The purpose









Heparin 14 (45) 7 (63) 21 (50)
Loop diuretics 25 (81) 10 (91) 35 (83)
Low-fat diet, MCT oil 17 (55) 11 (100) 28 (67)
ACE inhibitors, ARB 23 (74) 9 (81) 32 (76)
Spironolactone 21 (67) 5 (45) 26 (62)
Antiarrhythmic medications 10 (32) 5 (45) 15 (36)
Octreotide 7 (23) 1 (9) 8 (19)
Iron  transfusion 4 (13) 6 (55) 10 (24)
Sildenaﬁl 6 (19) 1 (9) 7 (17)
Steroids 9 (29) 3 (27) 12 (29)
Surgical/interventional therapies
Fontan fenestration 16 (52) 5 (45) 21 (50)
Fontan conversion* 7 (23) 2 (18) 9 (21)
Fontan obstruction relief 7 (23) 2 (18) 9 (21)
Ablation therapy 15 (48) 8 (73) 23 (55)
Valve replacement, repair,
or closure
3 (10) 1 (9) 4 (10)
Values are n (%). *Performed for atrial arrhythmias (7 cases) and obstruction
(2 cases).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
MCT ¼ medium chain triglycerides; other abbreviation as in Table 1.
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58of our study was to examine the survival rate of
patients with PLE following the Fontan operation in
the current era. In addition, we identiﬁed factors
that are associated with decreased survival and
described current treatment strategies for patients
with PLE following the Fontan operation (Central
Illustration). Because all patients had PLE, no con-
clusions can be made from this study about the risk
factors for the development of PLE.
Survival in our cohort was markedly improved
from previous reports. Patients had an 88% and 72%
survival rate at 5 and 10 years, respectively, after PLE
diagnosis. Recent single-center studies have reported
similar ﬁndings of improved survival after diagnosis
with PLE (7). These improved survival rates may be
partly due to improved survival rates following the
Fontan operation; however, the timing of surgery
was not associated with survival because 5 of the
11 deaths occurred in patients who had their original
Fontan operation performed after 1985 (8,9). In
addition, survivors were younger at the time of
diagnosis, which may be reﬂective of earlier diagnosis
and screening. There is still an increased mortality
rate for patients diagnosed with PLE following the
Fontan operation, but survival has markedly
improved regardless of when surgery was performed.
Patients with PLE at highest risk of mortality can be
identiﬁed on the basis of their hemodynamicparameters and laboratory assessment at initial
diagnosis. Low cardiac index has been thought to be
one of the causal factors in the development of PLE
following the Fontan operation (10). Similar to pre-
vious studies, all patients in our cohort had decreased
cardiac output, but those who died had a markedly
decreased cardiac index compared with survivors (1.6
 0.4 l/min/m2 vs. 2.7  0.7 l/min/m2, respectively).
Further evidence of low cardiac output as a risk factor
for mortality included lower mixed venous satura-
tion, NYHA functional class >II, and higher serum
creatinine levels in patients who died in this cohort
(Table 2, Fig. 2).
The causes of low cardiac output were multifacto-
rial. Patients who had mean pressures >15 mm Hg
within the Fontan pathway had decreased survival. In
addition, those patients with PLE who died had
higher pulmonary vascular resistance compared with
survivors. Both high Fontan pressures and high pul-
monary vascular resistance impede passive venous
return to the Fontan pathway, resulting in decreased
cardiac output. Decreased ventricular function also
was associated with decreased survival and repre-
sents another etiology for decreased cardiac output.
Interestingly, there was no statistical signiﬁcance for
the relationship between ventricular morphology and
survival. Atrial arrhythmias were common, occurring
in 67% of our patient cohort. Although the presence
of atrial arrhythmias was associated with decreased
survival, these results were not statistically signiﬁ-
cant. Patients who were responsive to antiarrhythmic
therapy had improved symptom control, likely due to
improved cardiac output.
All patients with PLE should undergo a compre-
hensive evaluation, as described in Table 4. Evalua-
tion is focused on determining both cardiac and
noncardiac causes of low cardiac output. Consulta-
tion with a gastroenterologist is recommended to rule
out other causes of PLE. In addition, evaluation
should be performed to rule out other causes of pro-
tein loss, such as nephrotic syndrome. Hepatic
dysfunction has been increasingly recognized in pa-
tients following the Fontan operation (11). Assess-
ment of hepatic dysfunction is important because
certain therapies, such as budesonide, are metabo-
lized through the liver (12). In addition, bleeding risk
may be increased in patients with hepatic dysfunc-
tion and should be considered before the initiation of
heparin therapy (13).
Because the cause of PLE can be multifactorial, it is
important to individualize the treatment plan for
each patient (14). A thorough, systematic approach is
needed to address all possible etiologies. A suggested
algorithm for treatment of PLE following the Fontan
Workup per Table 4:
Hospital admission for unstable/symptomatic patient
Consider IV diuretics/albumin therapy
Arrhythmia control
Intestinal Directed Therapies Cardiac Directed Therapies Extracardiac Directed Therapies
Low fat/high protein diet
Medium chain triglyceride oil
Consider:
      Heparin*
      CR-budesonide*
      Octreotide* 
  *Use with caution if hepatic
     dysfunction
Thyroid
Dysfunction 















Low Cardiac Output with:
  Elevated Fontan Pressure
           (> 15mmHg)
Decreased Ventricular








Consider:  Fontan fenestration,
PDE5 inhibitor, inhaled
prostacyclins, spirinolactone








CENTRAL ILLUSTRATION Treatment Algorithm for PLE After the Fontan Operation
Therapies must be individualized for each patient given the number of possible contributing factors. ACE ¼ angiotensin-converting enzyme;
ARB ¼ angiotensin receptor blocker; CR ¼ controlled release; IV ¼ intravenous; PDE5 ¼ phosphodiesterase 5; other abbreviations as in
Figures 1 and 2.
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59operation is presented in the Central Illustration. Most
patients in our cohort required multiple treatment
strategies, and an aggressive approach was used to
treat any potential causative factor.
For symptomatic patients, hospital admission
should be considered for stabilization, beginning with
a systematic evaluation and followed by initiation
of medical therapy with diuretics and albumin infu-
sion. Although albumin levels at diagnosis were
not associated with survival, administration of di-
uretics with albumin helps correct volume overload
and stabilize patients by transiently improving
intravascular volume. The ﬁrst step in treatment
should be aimed at addressing any cardiac etiologies,
speciﬁcally relieving any mechanical obstructions and
improving cardiac output (15). Atrial tachyarrhythmias
should be treated with cardioversion, ablation ther-
apy, and/or antiarrhythmic medications. Any patientwith atrial arrhythmias should be adequately treated
with anticoagulants. Establishing atrioventricular
synchrony should be the goal of the cardiac rhythm
management strategy.
Intestinal therapy is aimed at reducing enteric pro-
tein loss and improving nutritional status. Malnutri-
tion is common in PLE due to the fecal protein and fat
loss. Dietary recommendations for patients with PLE
include a high-protein ($2 g/kg/day), low-fat diet
(#25% of calories from fat) with medium-chain
triglyceride supplementation. Medium-chain triglyc-
eride supplements are absorbed directly into the
bloodstream, bypassing the damaged lymphatic sys-
tem in patients with PLE. Several strategies exist to
decrease enteric protein loss. Subcutaneous unfrac-
tionated heparin acts as a mechanical barrier by
decreasing permeability of the basal membrane
to large molecules such as albumin. In addition, it
TABLE 4 Suggested Evaluation of Patients With PLE





Presence of ascites, edema, cyanosis
Thyroid dysfunction
Liver dysfunction
Cardiac catheterization  cardiac MRI
Obstruction in Fontan pathway






Evaluation for hepatic dysfunction





Suggestion of Fontan obstruction
Aortic coarctation






Basic metabolic proﬁle with BUN/Cr




Urine analysis for protein
Stool alpha 1 antitrypsin level
BUN ¼ blood urea nitrogen; Cr ¼ creatinine; ECG ¼ electrocardiogram; GI ¼
gastrointestinal; MRI ¼ magnetic resonance imaging; other abbreviation as
in Table 1.
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60may decrease inﬂammation and potential micro-
thrombi to the mesenteric arteries. Budesonide, an
enteric-speciﬁc steroid, also targets inﬂammation and
has been used successfully to treat PLE in patients with
preserved liver function. Extracardiac conditions that
may have altered cardiac hemodynamics included
anemia, thyroid dysfunction, and sleep apnea. Both
intestinal- and extracardiac-directed therapy can be
instituted simultaneously but should not occur in
place of a thorough cardiac evaluation and treatment
plan.
Surgical or interventional treatments, which were
more frequently used in survivors, included relief
of Fontan obstruction and creation of a fenestration
within the Fontan pathway. Both therapies improvecardiac output and target elevated Fontan pressures.
With fenestration creation, it is important that pa-
tients are placed on some form of anticoagulation
because they are at higher risk for embolic phenom-
ena (16). Fontan conversion from an atriopulmonary
connection to an extracardiac conduit was performed
in the setting of refractory atrial arrhythmias in
7 patients and to relieve Fontan obstruction in 2 pa-
tients. Fontan conversion also was used more
frequently in survivors; however, Fontan revision for
primary treatment of PLE has not been met with good
results (17). Severe cardiac valve regurgitation was
treated surgically in 4 patients, with improvement in
symptoms in 3 patients. Consideration for valve repair
should be made on a case-by-case basis (18). Surgical
interventions carry a high risk of mortality in patients
with PLE; therefore, any treatment strategy should be
on the basis of the clinical case and risk to the patient
(1). Cardiac transplantation has been reported as a
potential treatment strategy andwas successfully used
in 1 of the patients within our cohort (7).
Medical treatments that were used more fre-
quently in survivors in our cohort included sildenaﬁl,
spironolactone, and octreotide. Sildenaﬁl, a pulmo-
nary vasodilator, works to decrease pulmonary vas-
cular resistance and has been shown to improve
some parameters of ventricular function and exercise
capacity in patients after the Fontan operation
(19,20). More recently, inhaled prostacyclins have
been shown to improve exercise capacity in patients
following the Fontan operation and may be useful in
the treatment of PLE (21). Inhaled agents have the
advantage of minimal systemic side effects, such as
the systemic vasodilation that has been observed
with sildenaﬁl. Spironolactone has been shown to be
effective in the treatment of PLE in Fontan patients
(22). Although the effects have been attributed to
improved cardiac function and its diuretic properties,
spironolactone also has been shown to improve
endothelial cell function and reduce inﬂammation
(23). Initial reports have been published suggesting
that spironolactone, in combination with endothelin
A receptor antagonists, improves exercise capacity in
patients with pulmonary arterial hypertension (24).
Further study is needed to determine the exact
mechanism of spironolactone in patients with PLE
after the Fontan operation. Octreotide, a somastatin
analogue, also was used with some success in our
cohort, although the experience is limited (25).
Octreotide decreases lymphatic ﬂow but does in-
crease gallstone formation. It should not be used as
an initial therapy, but as an adjunct in a treatment
regimen that targets cardiac and other intestinal
etiologies.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: PLE occurs in
5% to 15% of patients following the Fontan operation.
COMPETENCY IN PATIENT CARE: PLE following the Fontan
operation remains difﬁcult to treat. However, survival has
improved with a systematic approach to evaluation, as well as
individualized treatment.
TRANSLATIONAL OUTLOOK: The etiology of PLE following
the Fontan operation is multifactorial, and further studies are
needed to determine the ideal treatment strategy.
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61STUDY LIMITATIONS. Although this report includes a
large cohort of patients with PLE following the Fon-
tan operation, there are several limitations. All pa-
tients were evaluated at the Mayo Clinic during their
disease course with PLE; however, not all patients
were initially diagnosed with PLE at our center, and
diagnostic studies at initial diagnosis were not avail-
able for all patients. In addition, the initial Fontan
operation was performed at the Mayo Clinic in only
60% of patients. Therefore, no conclusions can be
made on the incidence of PLE following the Fontan
operation. Although the improved survival rate may
be reﬂective of earlier diagnosis, referral, and treat-
ment strategies at the Mayo Clinic, the mortality rate
may actually be an underestimation because it re-
ﬂects those who were well enough to pursue care at
the Mayo Clinic. The survival rate reﬂects the popu-
lation of patients with PLE following the Fontan
operation seen at the Mayo Clinic from 1992 to 2010.
Ventricular function at diagnosis was obtained
through estimated EF from echocardiography.
Assessment of ventricular function through magnetic
resonance imaging was not available for most pa-
tients. Time points of follow-up were variable among
patients. Therefore, detailed statistical analysis of
treatment strategies was not performed.
CONCLUSIONS
PLE following the Fontan operation remains difﬁcult
to treat; however, survival has improved withimproved treatment strategies. A systematic ap-
proach to evaluation and an individualized treatment
plan is important to maximize effective therapy.
Further multicenter studies are needed to determine
the ideal treatment strategy.
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